New drug picankibart aims to treat stubborn hand and foot pustules

NCT ID NCT07552454

Recruiting now Disease control Sponsor: Xijing Hospital Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a drug called picankibart in 60 adults with moderate-to-severe palmoplantar pustulosis, a painful skin condition causing pus-filled blisters on hands and feet. Participants receive injections of picankibart over nearly a year. The goal is to see if it reduces the severity of the rash and is safe.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Picankibart (a drug given as an injection under the skin)
What this could lead to: If this works, it could offer a new treatment option for people with stubborn palmoplantar pustulosis who haven't responded to standard therapies.
What could go wrong: This is a small, early-stage trial with no comparison group, so results may not be definitive. Side effects are possible, and the drug may not work for everyone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PALMOPLANTAR PUSTULOSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

palmoplantar pustulosis psoriasis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PALMOPLANTAR PUSTULOSIS

Contacts and locations

Locations

Department of Dermatology, Xijing Hospital, Fourth Military Medical University, No. 127 of West Changle Road, 710032, Xi'an, Shaanxi, China
RECRUITING

Xi'an, Shaanxi, 710032, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.